Merck beats forecast, but issues cautious 2013 view
(Reuters) – Merck & Co’s quarterly results beat forecasts, helped by strong sales of its Januvia diabetes drug and Gardasil vaccine against cervical cancer, but the company issued a full-year 2013 profit view at the low end of Wall Street expectations The No. 2 U. S. drugmaker on Friday said it earned $1. 4 billion, or 46 cents per share, in the fourth quarter. That compared with $1. 51 billion, or 49 cents per share, in the year-earlier period, when the company took charges for acquisition and restructuring expenses. Excluding special items, Merck earned 83 cents per share. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply